DNAlite Therapeutics
Founded
2016
2016
Geography
United States of America based
United States of America based
Funding
$1.500 M
$1.500 M
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.
Technologies
Gene Therapy StartupsR&D Platform
Pipelines
No pipelines published yet
Products
Services
No services posted yet